• Context Therapeutics posted a net loss of $14.56 million for Q2 2026, widening 65% from a year earlier.
• Operating loss widened 53% to $14.97 million as research and development expense climbed 60% to $12.53 million.
• General and administrative expense rose 26% to $2.44 million, while interest income fell 54% to $418,663.
• Cash and cash equivalents totaled $43 million at June 30, 2026; it sees liquidity lasting into Q4 2027.
• Portfolio reprioritization disclosed Aug. 5, 2026, discontinuing internal CT-95 development to focus on CTIM-76 and CT-202.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-053347), on August 05, 2026, and is solely responsible for the information contained therein.